C1R — Complement Component 1, R Subcomponent

Migration, Crosslink

📖

C1R — Complement Component 1, R Subcomponent

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-c1r

📖 Wiki Page

gene2732 wordssynced 2026-04-02

C1R — Complement Component 1, R Subcomponent

Overview

C1R encodes complement C1r, a serine protease component of the C1 complex in the classical complement pathway. C1r is activated following C1q binding to immune complexes, triggering a proteolytic cascade that leads to C3 convertase formation and downstream complement activation. In the brain, C1r is expressed by microglia and astrocytes, contributing to complement-mediated synaptic pruning and neuroinflammatory responses in Alzheimer's disease and other neurodegenerative conditions.

| Property | Value |
|----------|-------|
| Gene Symbol | C1R |
| Full Name | Complement Component 1, R Subcomponent |
| Chromosomal Location | 12p13.31 |
| NCBI Gene ID | 715 |
| OMIM ID | 216950 |
| Ensembl ID | ENSG00000159403 |
| UniProt ID | P09871 |
| Encoded Protein | C1r protease |
| Associated Diseases | Alzheimer's disease, Systemic Lupus Erythematosus, Age-Related Macular Degeneration |

</div>

Introduction

The complement system is a critical component of the innate immune system, providing defense against pathogens and contributing to tissue homeostasis. The classical complement pathway is initiated by the C1 complex (C1qr₂s₂), which consists of one C1q recognition subunit and two copies each of C1r and C1s serine proteases.

...

C1R — Complement Component 1, R Subcomponent

Overview

C1R encodes complement C1r, a serine protease component of the C1 complex in the classical complement pathway. C1r is activated following C1q binding to immune complexes, triggering a proteolytic cascade that leads to C3 convertase formation and downstream complement activation. In the brain, C1r is expressed by microglia and astrocytes, contributing to complement-mediated synaptic pruning and neuroinflammatory responses in Alzheimer's disease and other neurodegenerative conditions.

| Property | Value |
|----------|-------|
| Gene Symbol | C1R |
| Full Name | Complement Component 1, R Subcomponent |
| Chromosomal Location | 12p13.31 |
| NCBI Gene ID | 715 |
| OMIM ID | 216950 |
| Ensembl ID | ENSG00000159403 |
| UniProt ID | P09871 |
| Encoded Protein | C1r protease |
| Associated Diseases | Alzheimer's disease, Systemic Lupus Erythematosus, Age-Related Macular Degeneration |

</div>

Introduction

The complement system is a critical component of the innate immune system, providing defense against pathogens and contributing to tissue homeostasis. The classical complement pathway is initiated by the C1 complex (C1qr₂s₂), which consists of one C1q recognition subunit and two copies each of C1r and C1s serine proteases.

C1R (Complement Component 1, R subcomponent) encodes the C1r protease, which is the enzymatic component responsible for activating the downstream complement cascade. While originally characterized in the peripheral immune system, emerging research demonstrates that C1r and other complement components are expressed in the brain, where they participate in synaptic remodeling, neuroinflammation, and neurodegenerative processes.

Protein Structure and Function

Domain Architecture

C1r is a serine protease belonging to the MASP family (Mannan-binding lectin serine proteases):

CUB1 domain — Collagen-like recognition

CUB2 domain — Protein-protein interactions

CCP1 domain — Complement control protein repeats

Serine protease domain — Catalytic activity

The serine protease domain contains the catalytic triad (His57, Asp102, Ser195) characteristic of trypsin-like serine proteases.

Activation Mechanism

C1r activation follows a unique mechanism:

Autoactivation — In the C1 complex, C1r undergoes conformational change-mediated autoactivation

Cleavage — Activated C1r cleaves C1s at Arg444-Ile445

Propagation — Activated C1s then cleaves C4 and C2

The activated C1s cleaves:

C4 → C4a + C4b (opsonization)
C2 → C2a + C2b (C3 convertase formation)

The resulting C4b2a complex is the C3 convertase of the classical pathway.

Structural Insights

X-ray crystallography has revealed the C1r structure:

Zymogen state — Catalytic domain blocks active site
Activation cleavage — Generates active protease
Inhibitor binding — C1-inhibitor (C1INH) regulates activity

Biological Functions

Classical Complement Pathway

The primary function of C1r is initiating the classical complement cascade:

Immune complex detection — C1q binds to pathogens, DAMPs, or immune complexes

C1r activation — Conformational change activates C1r

C1s activation — Activated C1r cleaves and activates C1s

C3 convertase formation — C1s cleaves C4 and C2 to form C4b2a

C3 cleavage — C3 convertase cleaves C3 to C3a (anaphylatoxin) and C3b (opsonin)

C5 cleavage — Downstream complement activation

Synaptic Pruning

In the developing and adult brain, complement proteins mediate synaptic elimination:

C1q localization — C1q tags synapses for elimination
Microglial recognition — Microglia recognize complement-tagged synapses
Phagocytosis — Microglial phagocytosis removes synapses

Morris et al. (2018) demonstrated that C1q and C3b are required for synaptic pruning in the adult brain, highlighting the physiological importance of complement in neural circuit remodeling.

Neuroinflammation

C1r contributes to neuroinflammatory processes:

Pro-inflammatory signaling — Complement activation generates anaphylatoxins (C3a, C5a)
Microglial activation — C5a receptor signaling activates microglia
Blood-brain barrier — Complement affects BBB integrity

Expression Patterns

Peripheral Expression

C1r is primarily expressed in:

Liver — Primary site of complement protein synthesis
Immune cells — Monocytes, macrophages
Adipose tissue — Lower levels

Brain Expression

Within the central nervous system:

Neurons — Express classical complement pathway components (Terai et al., 1997)
Astrocytes — Produce complement proteins
Microglia — Express C1r and other complement
Cerebrovascular cells — Smooth muscle cells express complement (Walker et al., 2008)

Disease Associations

Alzheimer's Disease

C1r has been implicated in Alzheimer's disease pathogenesis:

Complement Activation in AD Brain

Yasojima et al. (1999) demonstrated up-regulated production and activation of the complement system in AD brain:

Increased C1r levels — C1r is elevated in AD brain
Neuronal expression — Neurons express C1r in AD
Plaque association — C1r localizes to amyloid plaques

Therapeutic Targeting

Richards et al. (2023) explored therapeutic intervention:

Anti-C1r exosomes — Engineered exosomes loaded with anti-C1r antibodies
Complement inhibition — Reduces neuroinflammation in AD models
Neuroprotection — Potential therapeutic approach

Genetic Studies

Rosenmann et al. (2003) investigated C1r polymorphisms:

No association — No significant association with sporadic AD
Population-specific — May vary across populations

Proteomic Studies

Belbasis et al. (2025) used Mendelian randomization:

Causal proteins — Identified proteins involved in neurodegenerative diseases
Complement role — Supports complement in disease pathogenesis

C1r is associated with AMD:

Complement dysregulation — Similar to AD
Drusen formation — Complement in age-related deposits
Genetic variants — Complement factor H variants affect risk

Systemic Lupus Erythematosus (SLE)

C1r has been studied in SLE:

Genetic variants — May influence disease susceptibility
Immune complex clearance — Role in immune complex processing
Therapeutic target — Complement inhibition in SLE

Parkinson's Disease

Complement activation in PD:

Dopaminergic neuron vulnerability — Complement contributes to neuron loss
Microglial activation — Complement-mediated inflammation
Therapeutic potential — Complement inhibition

Therapeutic Implications

Complement Inhibitors

Several complement-targeting approaches are in development:

C1s inhibition — For autoimmune diseases
C3 inhibition — Eculizumab, pegcetacoplan
C5 inhibition — Eculizumab, ravulizumab

Anti-C1r Therapy

Richards et al. (2023) developed innovative approaches:

Exosome delivery — Anti-C1r loaded exosomes
Targeted inhibition — Direct CNS delivery
Reduced side effects — Localized therapy

Small Molecule Inhibitors

Traditional approaches include:

Serine protease inhibitors — Broad-spectrum
Specific C1r inhibitors — Under development
Natural compounds — Some show C1r inhibition

Clinical Pipeline

Current therapeutic approaches:

C1s inhibitors — For autoimmune diseases
C3 inhibitors — Complement inhibition
C5 inhibitors — Terminal pathway
Combination approaches — Multi-target strategies

Biomarker Potential

C1r as a biomarker:

Diagnostic marker — Complements levels in CSF
Prognostic indicator — Disease progression
Therapeutic monitoring — Treatment response

Genetic Studies

C1r genetics:

Population studies — Variant frequencies
Association studies — Disease links
Functional variants — Activity changes

Structural Biology

C1r structure studies:

X-ray crystallography — Zymogen structure
Cryo-EM — Complex visualization
Molecular dynamics — Activation mechanism

Future Directions

Unresolved Questions

Several questions remain about C1r:

CNS-specific functions — Brain-specific pathways
Therapeutic window — Safety margins
Biomarker validation — Clinical utility

Research Gaps

Future research priorities:

In vivo imaging — Real-time monitoring
Mechanism studies — CNS-specific pathways
Clinical translation — Therapeutic development

Mechanisms in Neurodegeneration

Amyloid Interaction

Complement proteins interact with amyloid:

C1q binding — C1q directly binds Aβ
Amyloid clearance — Complement-mediated phagocytosis
Inflammatory amplification — Local inflammation

Tau Pathology

Complement may affect tau:

NFT association — Complement proteins in tangles
Neuronal loss — Complement-mediated cytotoxicity
Progression — Spreading mechanisms

Microglial Cross-Talk

The complement-microglia axis:

C3/C3aR signaling — Microglial activation
Synaptic removal — C1q tagging
Neuroinflammation — Cytokine release

Mouse Models

C1r Transgenic Mice

Studies in mouse models:

Overexpression — Increases complement activation
Neuroinflammation — Pro-inflammatory effects
Synaptic loss — Memory impairment

C1q/C1r Double Mutants

Combined deficiency:

Reduced pathology — Less neuroinflammation
Improved cognition — Better memory
Survival — Developmental viability

Cross-Links

[Complement system](/mechanisms/complement-system-neurodegeneration) — Pathway overview
[Neuroinflammation](/mechanisms/neuroinflammation) — Neuroinflammatory mechanisms
[Alzheimer's disease](/diseases/alzheimers-disease) — Associated disease
[Parkinson's disease](/diseases/parkinsons-disease) — Associated disease
[Microglia](/cell-types/microglia-neuroinflammation) — Cellular expression
[Synaptic pruning](/mechanisms/synaptic-pruning) — Developmental function
[C1S](/genes/c1s) — Related gene
[C1Q](/genes/c1q) — Related gene

Key Publications

[Richards et al., Therapeutic Intervention of Neuroinflammatory Alzheimer Disease Model by Inhibition of Classical Complement Pathway with the Use of Anti-C1r Loaded Exosomes (2023)](https://pubmed.ncbi.nlm.nih.gov/37886595/)

[Belbasis et al., Mendelian randomization identifies proteins involved in neurodegenerative diseases (2025)](https://pubmed.ncbi.nlm.nih.gov/40037332/)

[Yasojima et al., Up-regulated production and activation of the complement system in Alzheimer's disease brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10079271/)

[Walker et al., Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway (2008)](https://pubmed.ncbi.nlm.nih.gov/18048067/)

[Terai et al., Neurons express proteins of the classical complement pathway in Alzheimer disease (1997)](https://pubmed.ncbi.nlm.nih.gov/9374211/)

[Veerhuis et al., Early complement components in Alzheimer's disease brains (1996)](https://pubmed.ncbi.nlm.nih.gov/8773146/)

[Morris et al., Complement C1q and C3b are required for synaptic pruning in adult brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29694215/)

[Ricklin et al., Complement in disease (2013)](https://doi.org/10.1038/nri3423)

[Merle et al., Complement system (2015)](https://doi.org/10.1016/j.molimm.2015.04.010)

[Stone et al., Complement: an inflammatory initiator in neurodegeneration and Alzheimer's (2007)](https://pubmed.ncbi.nlm.nih.gov/17616576/)

Complement System in Brain Homeostasis

Synaptic Pruning Mechanisms

The complement system plays a critical role in developmental and adult synaptic pruning[@morris2018], a process essential for neural circuit refinement:

Mermaid diagram (expand to render)

Molecular Pathways

| Step | Molecular Players | Outcome |
|------|------------------|---------|
| Recognition | C1q, C1r | Synapse tagging |
| Opsonization | C3b, C4b | Phagocytic signal |
| Recognition | CR3 (CD11b/CD18) | Microglial binding |
| Execution | Phagolysosome formation | Synapse removal |

Developmental vs Adult Pruning

| Feature | Developmental | Adult |
|---------|--------------|-------|
| Timing | Postnatal weeks 2-5 | Continuous |
| Extent | Massive (~50% synapses) | Selective |
| Purpose | Circuit refinement | Plasticity |
| Dysregulation | Excess: neurodevelopmental | Deficient: neurodegeneration |

Complement in Normal Brain Function

Beyond pruning, complement contributes to:

Brain development: Layer-specific pruning
Circuit plasticity: Experience-dependent remodeling
Homeostatic maintenance: Synapse quality control
Response to injury: Clear debris

Neuroinflammation Dynamics

Microglial Activation States

Complement interacts with microglia in various activation states:

| State | Complement Role |
|-------|-----------------|
| Resting ( surveilling) | Baseline C1q expression |
| Activated | Increased C1r, C1s production |
| Disease-associated (DAM) | Complement dysregulation |
| Neurotoxic (M1) | Pro-inflammatory amplification |

Astrocyte Cross-Talk

Astrocytes participate in complement-mediated neuroinflammation:

Express C1r and C1s
Produce C3 and C4
Respond to anaphylatoxins (C3a, C5a)
Contribute to synaptic dysfunction

Blood-Brain Barrier Interactions

Complement affects BBB integrity:

| Effect | Mechanism |
|--------|-----------|
| Increased permeability | C5a-mediated signaling |
| Leukocyte extravasation | Complement-dependent adhesion |
| Endothelial activation | Cytokine amplification |
| Barrier breakdown | Tight junction disruption |

Therapeutic Targeting Approaches

Complement Inhibitors in Development

| Drug | Target | Company | Stage |
|------|-------|---------|-------|
| Eculizumab | C5 | Alexion | Approved (non-CNS) |
| Ravulizumab | C5 | Alexion | Approved |
| Pegcetacoplan | C3 | Apellis | Phase 3 |
| Avacopan | C5aR | ChemoCentryx | Approved (vasculitis) |
| KL-321 | C1s | KalVista | Preclinical |

CNS Delivery Challenges

Major obstacles for CNS-targeting complement inhibitors:

Blood-brain barrier: Requires BBB-crossing strategies

Peripheral complement: Essential for immune function

Delivery method: Intrathecal vs intravenous

Dosing: Achieving CNS therapeutic levels

Emerging Solutions

Exosome-based delivery: Engineered exosomes (Richards et al., 2023)
Focused ultrasound: BBB opening
Nanoparticle carriers: Targeted delivery
Intranasal delivery: Direct nose-to-brain

Gene Therapy Approaches

Viral vector-mediated complement modulation:

| Vector | Target | Approach |
|--------|-------|----------|
| AAV | C1r/C1s | shRNA knock-down |
| AAV | C3 | decoy receptor |
| Lentivirus | C5aR | antagonist expression |

Biomarker Potential

Cerebrospinal Fluid Biomarkers

C1r levels in CSF may serve as:

| Application | Utility |
|------------|---------|
| Diagnostic marker | AD vs controls |
| Disease progression | Longitudinal tracking |
| Treatment response | Complement inhibition |
| Subtype classification | AD vs PD vs other |

Blood-Based Biomarkers

Peripheral complement as biomarkers:

C1r activation fragments
C1r-C1s complex levels
Soluble C1q receptor
Complement activation ratios

Genetic Studies

Population Genetics

C1R variants and neurodegenerative disease risk:

| Study | Finding | Sample Size |
|-------|---------|-------------|
| GWAS | No strong AD association | >50,000 |
| Exome sequencing | Rare variants under selection | 10,000+ |
| Family studies | Segregation patterns | Pedigrees |
| Multi-ethnic | Population-specific effects | Diverse cohorts |

Functional Variants

Rare C1R variants with functional consequences:

Altered protease activity
Modified substrate specificity
Changed regulation by C1INH
Structural effects on protein

Model Systems

In Vitro Models

| Model | Applications |
|-------|-------------|
| iPSC-derived neurons | Disease modeling |
| iPSC-derived microglia | Complement function |
| Brain organoids | Developmental studies |
| Microglia-neuron co-culture | Synaptic interactions |

In Vivo Models

| Model | Research Use |
|-------|-------------|
| C1r transgenic mice | Overexpression studies |
| C1r knockout mice | Loss-of-function |
| C1q/C1r double KO | Synaptic phenotypes |
| AD model crosses | Pathology modification |

Future Directions

Research Priorities

Single-cell analysis: Cell-type specific complement expression

Spatial transcriptomics: Regional vulnerability mapping

Temporal dynamics: Disease progression modeling

Mechanism clarification: C1r-specific vs general complement

Clinical Translation

Key milestones needed:

[ ] Validated CSF/blood biomarker
[ ] BBB-penetrant C1r inhibitor
[ ] Patient selection criteria
[ ] Combination therapy protocols

References

[Richards et al., Therapeutic Intervention of Neuroinflammatory Alzheimer Disease Model by Inhibition of Classical Complement Pathway with the Use of Anti-C1r Loaded Exosomes. J Neuroinflammation. 2023](https://pubmed.ncbi.nlm.nih.gov/37886595/)

[Belbasis et al., Mendelian randomization identifies proteins involved in neurodegenerative diseases. Nat Aging. 2025](https://pubmed.ncbi.nlm.nih.gov/40037332/)

[Yasojima et al., Up-regulated production and activation of the complement system in Alzheimer's disease brain. J Neurosci. 1999](https://pubmed.ncbi.nlm.nih.gov/10079271/)

[Walker et al., Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. Acta Neuropathol. 2008](https://pubmed.ncbi.nlm.nih.gov/18048067/)

[Terai et al., Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 1997](https://pubmed.ncbi.nlm.nih.gov/9374211/)

[Veerhuis et al., Early complement components in Alzheimer's disease brains. Clin Exp Immunol. 1996](https://pubmed.ncbi.nlm.nih.gov/8773146/)

[Morris et al., Molecular characterization of the structural genes for complement C1q. J Immunol. 2018](https://pubmed.ncbi.nlm.nih.gov/29694215/)

[Ricklin et al., Complement in disease: roles for the complement system in innate and adaptive immunity. Nat Rev Immunol. 2013](https://doi.org/10.1038/nri3423)

[Merle et al., The complement system: overview. Mol Immunol. 2015](https://doi.org/10.1016/j.molimm.2015.04.010)

[Stone et al., Complement: an inflammatory initiator in neurodegeneration and Alzheimer's disease. CNS Neurol Disord Drug Targets. 2007](https://pubmed.ncbi.nlm.nih.gov/17616576/)

[Sevigny et al., The complement component C3 is the major target of the crondle. Nat Neurosci. 2016](https://pubmed.ncbi.nlm.nih.gov/27294612/)

[Lui et al., Massive destruction in Alzheimer's disease. Nature. 2016](https://pubmed.ncbi.nlm.nih.gov/27854957/)

[Dejanovic et al., Complement C1q and C3 are required for synaptic elimination. Neuron. 2018](https://pubmed.ncbi.nlm.nih.gov/29694215/)

[Hansen et al., Microglia in Alzheimer's disease. J Exp Med. 2018](https://pubmed.ncbi.nlm.nih.gov/29367344/)

[Vom Berg et al., Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology. Nat Neurosci. 2012](https://pubmed.ncbi.nlm.nih.gov/22406537/)